AAV-alpha galactosidase A gene therapy (Genzyme)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAAV-alpha galactosidase A gene therapy (Genzyme)

Drug Alias NameAAV2/CMVH1-alpha galactosidase A gene therapy (Genzyme)Fabry disease gene therapy (Genzyme)

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector

Mechanisms of Actionα-Galactosidase stimulants

Targetsα-Galactosidase

Therapy Area/IndicationsFabry Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGenzyme Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenzyme Corp

Active IndicationsN/A

Inactive IndicationsFabry Disease

Other Information

ATC CodeN/A